5UEM image
Entry Detail
PDB ID:
5UEM
Keywords:
Title:
Crystal structure of 354NC37 Fab in complex with HIV-1 clade AE strain 93TH057 gp120
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2017-01-02
Release Date:
2018-01-10
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.26
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:clade A/E 93TH057 HIV-1 gp120 core
Chain IDs:A (auth: G)
Chain Length:361
Number of Molecules:1
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Description:354NC37 Fab Heavy Chain
Chain IDs:B (auth: H)
Chain Length:230
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:354NC37 Fab Light Chain
Chain IDs:C (auth: L)
Chain Length:213
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation

Abstact

Some HIV-1-infected patients develop broad and potent HIV-1 neutralizing antibodies (bNAbs) that when passively transferred to mice or macaques can treat or prevent infection. However, bNAbs typically fail to neutralize coexisting autologous viruses due to antibody-mediated selection against sensitive viral strains. We describe an HIV-1 controller expressing HLA-B57*01 and HLA-B27*05 who maintained low viral loads for 30 years after infection and developed broad and potent serologic activity against HIV-1. Neutralization was attributed to three different bNAbs targeting nonoverlapping sites on the HIV-1 envelope trimer (Env). One of the three, BG18, an antibody directed against the glycan-V3 portion of Env, is the most potent member of this class reported to date and, as revealed by crystallography and electron microscopy, recognizes HIV-1 Env in a manner that is distinct from other bNAbs in this class. Single-genome sequencing of HIV-1 from serum samples obtained over a period of 9 years showed a diverse group of circulating viruses, 88.5% (31 of 35) of which remained sensitive to at least one of the temporally coincident autologous bNAbs and the individual's serum. Thus, bNAb-sensitive strains of HIV-1 coexist with potent neutralizing antibodies that target the virus and may contribute to control in this individual. When administered as a mix, the three bNAbs controlled viremia in HIV-1YU2-infected humanized mice. Our finding suggests that combinations of bNAbs may contribute to control of HIV-1 infection.

Legend

Protein

Chemical

Disease

Primary Citation of related structures